Response to first-line chemotherapy and long-term survival in patients with multiple myeloma

Autor:	C Delfini, G Nicoletti, L Piccinini, Silvia Brugnatelli, Carmine Tinelli, Monica Giordano, B Tolcà, Edoardo Ascari, A. De Paoli, Anna Riccardi, D Grasso, Luciana Barbarano, Camillo Porta, Marco Danova, Luigi Cavanna, O Mora, C Bergonzi, E Rinaldi, R Spanedda
Rok vydání:	2003
Předmět:	Cancer Research medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Induction chemotherapy Disease medicine.disease Gastroenterology Surgery Stable Disease Oncology Internal medicine Immunopathology medicine In patient business Progressive disease Multiple myeloma
Zdroj:	European Journal of Cancer. 39:31-37
ISSN:	0959-8049
DOI:	10.1016/s0959-8049(02)00529-4
Popis:	In this study we evaluated whether a good response to conventional chemotherapy, i.e. a significant tumour reduction, is a prerequisite for improved survival in multiple myeloma (MM). Between January 1987 and March 1990, 341 consecutive previously untreated patients with MM received chemotherapy within the prospective, multicentre, randomised Protocol MM87. Of these, 258 patients were evaluable for both response and long-term survival and 244 (94.6%) have died. The median survival of all patients was 40 months (6–162 months). The median survival did not differ between patients who had complete response (CR) (50 months (9–162 months)), partial response (PR) (46 months (8–147 months)) or stable disease (SD) (41 months (7–135 months)). The median survival was shorter (13.6 months (6–135 months)) (P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::bc528e7cc60bdfefd4893029f926e190 https://doi.org/10.1016/s0959-8049(02)00529-4 Zobrazit plný text záznamu Full Text from ScienceDirect